Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes

被引：0
|
作者：
Herbst, Roy S. [1 ]
Stern, Howard [2 ]
Amler, Lukas [2 ]
Otterson, Gregory [3 ]
Lin, Ming [2 ]
O'Connor, Paula [2 ]
Hainsworth, John [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Sarah Cannon Rsrch Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [31] A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy.: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial.
    Shepherd, FA
    Pereira, J
    Ciuleanu, TE
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Bezjak, A
    Tu, D
    Santabárbara, P
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 622S - 622S
  • [32] Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer
    Liu, Geoffrey
    Cheng, D.
    Ding, K.
    Le Maitre, A.
    Liu, N.
    Patel, D.
    Chen, Z.
    Seymour, L.
    Shepherd, F. A.
    Tsao, M. S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 316 - 322
  • [33] PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).
    Sorlini, C.
    Barni, S.
    Petrelli, F.
    Novello, S.
    De Marinis, F.
    De Pas, T. M.
    Grossi, F.
    Bearz, A.
    Mencoboni, M.
    Aieta, M.
    Caprioli, A.
    Antonelli, P.
    Zilembo, N.
    Bachi, A.
    Floriani, I.
    Roder, H.
    Roder, J.
    Grigorieva, J.
    Lazzari, C.
    Gregorc, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Stevenson, James
    Sulecki, Matthew Gerard
    Hugec, Vladimir
    Choong, Nicholas W.
    Saltzman, Joel N.
    Song, Wei
    Hansen, Richard M.
    Evans, Tracey L.
    Ramalingam, Suresh S.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II
    Mok, Tony
    Wu, Yi Long
    Thongprasert, Sumitra
    Yu, Chong-Jen
    Zhang, Li
    Ladrera, Guia Elena
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Sandoval-Tan, Jennifer
    Zhu, Yunzhong
    Liao, Meilin
    Zhou, Caicun
    Pan, Hongming
    Lee, Victor
    Chen, Yuh-Min
    Sun, Yan
    Margono, Benjamin
    Jin, Kate
    Truman, Matt
    Lee, Jin Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Johnson, Bruce E.
    Kabbinavar, Fairooz
    Fehrenbacher, Louis
    Hainsworth, John
    Kasubhai, Saifuddin
    Kressel, Bruce
    Lin, Chin-Yu
    Marsland, Thomas
    Patel, Taral
    Polikoff, Jonathan
    Rubin, Mark
    White, Leonard
    Yang, James Chih-Hsin
    Bowden, Chris
    Miller, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3926 - +
  • [38] A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study
    Groen, H.
    Hochstenbag, M. M.
    van Putten, J. W.
    Vincent, A.
    Dalesio, O.
    Biesma, B.
    Smit, H. J.
    Termeer, A.
    van den Borne, B. E.
    Schramel, F. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Predicting Treatment Response to 1st-line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression
    Janzen, I.
    Abraham, R.
    Seyyedi, S.
    Ho, C.
    Melosky, B.
    Martin, M.
    Lam, S.
    Yuan, R.
    Macaulay, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1138 - S1138
  • [40] Celecoxib in docetaxel/carboplatin treated patients (pts) with advanced non-small cell lung cancer (NSCLC): interaction of treatment with histology; a randomized placebo-controlled phase III study of the NVALT Group
    Groen, Harry J.
    van Putten, John W.
    Hochstenbag, Monique M.
    Vincent, Andrew
    Dalesio, Otilia
    Smit, Hans J.
    Termeer, Rene
    van den Borne, Ben E.
    Biesma, Bonne
    Schramel, Franz M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S382 - S382
12345